Tag | (0018,9337) |
---|---|
Type | Required (1) |
Keyword | ContrastBolusAgentNumber |
Value Multiplicity | 1 |
Value Representation | Unsigned Short (US) |
Identifying number corresponding to the agent described in the Enhanced Contrast/Bolus Module.
Part of the Contrast/Bolus Usage Functional Group Macro with usage: U
Table C.7-12b specifies the Attributes of the Enhanced Contrast/Bolus Module, which describe the contrast/bolus used in the acquisition of the Image.
Table C.7-12b. Enhanced Contrast/Bolus Module Attributes
Attribute Name |
Tag |
Type |
Attribute Description |
---|---|---|---|
Contrast/Bolus Agent Sequence |
(0018,0012) |
1 |
Sequence that identifies one or more contrast agents administered prior to or during the acquisition. One or more Items shall be included in this Sequence. |
>Contrast/Bolus Agent Number |
(0018,9337) |
1 |
Identifying number, unique within this SOP Instance, of the agent administered. Used to reference this particular agent from the Contrast/Bolus Functional Group Macro. The number shall be 1 for the first Item and increase by 1 for each subsequent Item. |
>Contrast/Bolus Administration Route Sequence |
(0018,0014) |
1 |
Sequence that identifies the route of administration of contrast agent. Only a single Item shall be included in this Sequence. |
>Contrast/Bolus Ingredient Code Sequence |
(0018,9338) |
2 |
Active ingredient of agent. Zero or more Items shall be included in this Sequence. |
>Contrast/Bolus Volume |
(0018,1041) |
2 |
Total volume administered in milliliters of diluted contrast agent. |
>Contrast/Bolus Ingredient Concentration |
(0018,1049) |
2 |
Milligrams of active ingredient per milliliter of agent. |
>Contrast/Bolus Ingredient Percent by Volume |
(0052,0001) |
3 |
Percentage by volume of active ingredient in the total volume. |
>Contrast/Bolus Ingredient Opaque |
(0018,9425) |
3 |
Absorption of the ingredient greater than the absorption of water (tissue). Enumerated Values:
See Section C.7.6.4b.1. |
>Contrast/Bolus T1 Relaxivity |
(0018,0013) |
3 |
T1 Relaxivity of the MR Contrast/Bolus used specified in s-1*mmol-1 specified at body temperature in human blood plasma. |
>Contrast Administration Profile Sequence |
(0018,9340) |
3 |
Sequence that describes one or more phases of contrast administered. One or more Items are permitted in this Sequence. |
>>Contrast/Bolus Volume |
(0018,1041) |
2 |
Volume administered during this phase in milliliters of diluted contrast agent. |
>>Contrast/Bolus Start Time |
(0018,1042) |
3 |
Time of start of administration. |
>>Contrast/Bolus Stop Time |
(0018,1043) |
3 |
Time of end of administration. |
>>Contrast Flow Rate |
(0018,1046) |
3 |
Rate of administration in milliliters/sec. Only a single value shall be present. |
>>Contrast Flow Duration |
(0018,1047) |
3 |
Duration of injection in seconds. Only a single value shall be present. |
Contrast/Bolus Ingredient Opaque (0018,9425) Attribute specifies the type of relative X-Ray absorption of the contrast/bolus ingredient, compared to the X-Ray absorption of water.
Enumerated Values:
The contrast/bolus ingredient absorbs more X-Ray photons than water
The contrast/bolus ingredient absorbs less X-Ray photons than water
The Contrast/Bolus Ingredient Opaque (0018,9425) Attribute determines the sign of the gradient of X-Ray beam intensity from inside to outside the injected vessel, thus allowing optimal settings of the image processing applications (e.g., vessel edge detection, etc.), see Figure C.7.6.4b-1.
The relative gray level of the injected vessel with respect to the gray level of the water of Pixel Data (7FE0,0010) is determined by the Contrast/Bolus Ingredient Opaque (0018,9425) and by the Pixel Intensity Relationship Sign (0028,1041). For example, if the contrast/bolus ingredient is more radio graphically dense than water (i.e., YES), and the Pixel Intensity Relationship Sign (0028,1041) is -1, then the contrast/bolus ingredient is represented by higher values of Pixel Data than water.
Figure C.7.6.4b-1. X-Ray beam intensity vs. Contrast/Bolus Ingredient Opaque